The popularity of Sildenafil initially sparked a boom for major pharmaceutical companies, but recent changes present a complicated outlook for shareholders. Lower-cost versions are eating into profits, and continued https://pennywshk325166.blogunteer.com/39893724/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-play